A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Inclusion Criteria

• Provide written informed consent
• Women of child-bearing potential must have a negative pregnancy test Multiple Myeloma: Confirmed diagnosis of Multiple Myeloma with measurable disease, having been treated with at least two prior lines of therapy. Lymphoma: Confirmed diagnosis of Non-Hodgkin Lymphoma with measurable disease, having been treated with at least one anthracycline-based therapy, with relapse or progression since the last treatment received.

Exclusion Criteria

• Any of the following treatments, within the specified time frame, prior to the first dose of TAS4464:
• Major surgery within 28 days
• Radiation/chemotherapy within 21 days
• Monoclonal antibodies within 28 days
• Corticosteroid administration >20 mg/day of prednisone or equivalent within 14 days
• Proteasome inhibitors within 14 days
• Immunomodulatory agents within 7 days
• Stem cell transplant within 3 months
• Current immunosuppressive treatment for graft versus host disease
• Current use of an investigational agent
• Active graft versus host disease
• Known serious illness or medical condition
• Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class
• Pregnant or breast-feeding female